ACT-IOP-003 / Focal Medical - LARVOL DELTA

Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer (Businesswire) - "Focal Medical, Inc...announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product. The trial will evaluate the safety and tolerability of targeted delivery of gemcitabine to locally advanced nonresectable (LANR) pancreatic tumors. The clinical trial is expected to start mid-2024....Up to 12 patients may be enrolled in the study which is expected to start mid-2024."

IND • New P1 trial • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor